Innoviva, Inc. (INVA) fair value analysis

Nasdaq · Updated 2026-09-07

Innoviva, Inc. is a biopharmaceutical company that develops and commercializes respiratory medicines, primarily focusing on chronic obstructive pulmonary disease and asthma treatments. The company operates in the United States and internationally, with its primary operations and headquarters based in the United States.

Forward Fair Value verdict

Fairly valued

Based on TickrTrends' weekly Forward Fair Value model, INVA is trading at within about 10% of estimated fair value.

INVA currently ranks #60 of 113 Healthcare stocks by discount to Forward Fair Value. It has screened as Fairly valued for 3 consecutive weekly runs.

Last price: $20.77
Sector: Healthcare
12-month range: $18.11–$23.41

Derived indicators

Coarse bands from TickrTrends' weekly models; exact figures are part of the full report.

Quality grade: B
Leverage: Low
RSI zone: Neutral
50/200-day trend: Downtrend
52-week position: The upper-middle quarter of its range

What our data shows for INVA

Our model validated 14 trailing price-to-earnings windows for INVA, built from quarterly earnings records.
Shares are trading in the middle of their 12-month price range of $18.11–$23.41.
The 14-day relative strength index sits at a neutral 60.

The exact numbers are one step away

The precise Forward Fair Value dollar figure for INVA
Exact discount / premium to today's price
The normalized historical P/E behind the estimate, and how many quarters support it
Forward EPS input and fiscal-year basis
Screeners and rankings across the full S&P 500 and Nasdaq universes

See the exact fair value →

How Forward Fair Value works

TickrTrends computes a Forward Fair Value for every covered stock each week: a conservatively normalized historical price-to-earnings multiple is applied to the analyst-consensus earnings estimate for the next full fiscal year. Every input window is validated for continuity and every result is screened for plausibility before publication.

Recent INVA news

TickrTrends' derived news-sentiment signal for INVA is currently leaning positive, computed from recent coverage.

Innoviva: The Royalty Decline Is Real, But The Valuation Is Too Pessimistic (NASDAQ:INVA) (seekingalpha.com, 2026-08-06)
TickrTrends take: Innoviva trades at a valuation that TickrTrends currently considers fairly valued despite market concerns about declining royalty revenues in its healthcare business model. The headline suggests that while the company faces genuine headwinds from royalty erosion, the market may be pricing in more pessimism than the current fundamentals warrant. Investors focused on valuation should monitor whether royalty decline rates stabilize or accelerate, as this will be critical to determining whether the fair value assessment holds.
Dr Reddy’s, GARDP get Thai FDA’s nod for Nuzolvence (thehindubusinessline.com, 2026-07-27)
TickrTrends take: Innoviva Inc (INVA) operates in the Healthcare sector and is currently assessed as fairly valued according to TickrTrends. While the headline concerns Dr Reddy's and GARDP receiving Thai FDA approval for Nuzolvence, investors should monitor whether such regulatory developments in antibiotic treatments create competitive pressures or partnership opportunities that could affect INVA's market position and asset valuation. The healthcare regulatory environment remains dynamic, and approval timelines for similar therapeutics may influence sector-wide valuation multiples that could eventually impact fairly valued assessments.
Innoviva, Inc. (INVA) Launches Nortiva Bio to Advance Long-Acting Oral Drug Platform (finance.yahoo.com, 2026-06-25)
TickrTrends take: Innoviva's launch of Nortiva Bio to develop a long-acting oral drug platform represents a significant capital allocation toward pipeline expansion in the Healthcare sector. With INVA currently assessed as fairly valued by TickrTrends, investors should monitor whether this new subsidiary generates meaningful clinical or commercial progress that could justify valuation expansion or alternatively requires ongoing capital deployment that might pressure near-term returns. The success of this platform initiative will be a key factor in determining whether the current valuation assessment remains appropriate as the company advances these development programs.

What people are saying

Follow the INVA conversation: Stocktwits · Reddit · X

TickrTrends weekly updates

2026-09-07 — No material change this week: the verdict, bands and grades all held steady.
2026-09-06 — INVA's momentum indicator, which was rated B last week, has moved to none this week. The stock remains fairly valued according to current valuation metrics. This change in momentum tracking represents the only shift in TickrTrends' derived indicators for the Healthcare sector company during the week.
2026-08-31 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.

Frequently asked questions

Is INVA stock undervalued?

Based on TickrTrends' Forward Fair Value model (updated 2026-09-07), INVA is trading at within about 10% of estimated fair value and screens as fairly valued. The exact fair value and discount are available to subscribers.

What is INVA's TickrTrends verdict?

INVA's current verdict is Fairly valued, refreshed with every weekly Forward Fair Value run.

How does INVA compare to other Healthcare stocks?

INVA ranks #60 of 113 Healthcare stocks in TickrTrends' coverage when sorted by discount to Forward Fair Value.

Is INVA overbought or oversold?

INVA's 14-day RSI is in neutral territory - neither overbought nor oversold.

All Healthcare fair-value coverage →

Head-to-head comparisons

INVA vs A · INVA vs DHR · INVA vs ENSG · INVA vs KNSA · INVA vs MDT